MiRNA-based therapy for Breast Cancer: MiRNA-137 increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients, 13/November/2015, 9.01 am

Molecular therapy for Myocardial Infarction: miR-380-5p improves myocardial function after myocardial infarction via up-regulation of PNUTS, 11/November/2016, 11.22 pm
November 12, 2016
Natural product therapy for KRAS-mutant lung cancer: Epigallocatechin gallate, one of the main components of Green tea, decreases the expression of XPO1, increases the level of NFKBIA, inhibits NFKB transcriptional activity and suppresses the progression of KRAS-mutant lung cancer via up regulation of its target gene, 13/November/2016, 9.20 am
November 13, 2016
Show all

What they say: 

A study from the Division of Molecular Medicine and Genetics, Department of Internal Medicine, The Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA shows that “Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer” This study was published in the 17 October 2016 issue of the journal “Nature Cell Biology” [the number 1 journal in Cell Biology with an I.F of 18.699] by Prof. Stephen J. Weiss, Ting Ne, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Breast Cancer: MiRNA-137 increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients


Significance:

Given that: (1) cancer causes the highest economic loss compared to all the known causes of death worldwide; (2) in 2008, breast cancer has caused more than 400000 deaths; (3) in 2011, 17 lakhs new cases of breast cancer diagnosed; (4) breast cancer is the most common invasive cancer in women; and (5) in 2008, breast cancer has caused economic loss of 88 billion US dollars worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of breast cancer.

Breast cancer is the most common women cancer. Interestingly, compared to other women cancers, breast cancer not only metastasizes frequently but also relapses. However, the mechanistic basis of which remains largely unclear.


What we infer from what they say:

Stephen’s research team has recently shown that increased expression of the EMT (Epithelial-to-mesenchymal transition) regulator Snail1 promotes: (1) degradation of tumor suppressor p53 in breast cancer cells; and (2) expansion and activity of tumor-initiating cells that aid in relapse of breast cancer, suggesting that inhibition of metastatic promoter Snail1 expression in breast cancer cells will not only inhibit the progression of metastatic breast cancer but also prevent relapse.


From research findings to therapeutic opportunity : 

This study suggests a small molecule-based therapy for metastatic breast cancer. MiRNA-137, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor p53. Thereby, it may inhibit metastasis and relapse of breast cancer.

Thus, pharmacological formulations encompassing MiRNA-137  activators may be used to treat metastatic breast cancer.


Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., MiRNA-based therapy for Breast Cancer: MiRNA-137 increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients, 13/November/2015, 9.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org


Amount: $100#

Undisclosed information: How MiRNA-137 increases the expression of tumor suppressor p53 and inhibits the proliferation of tumor-initiating cells in metastatic breast cancers?

Results guaranteed if not refundedguaranteed-to-work1

#Research cooperation

Comments are closed.